trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Immunotherapy treatments for cancer may cause flu-like symptoms or, in rare cases, severe reactions.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that immunotherapy treatments for cancer may cause flu-like symptoms or, in rare cases, severe reactions?

Yes. Immunotherapy treatments for cancer are well-documented to induce immune-related adverse events, ranging from common inflammatory reactions and flu-like symptoms to rare and severe complications like cytokine release syndrome or myotoxicity.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

The claim is specific, empirical, and directly addressed by multiple retrieved papers showing that cancer immunotherapy causes both common immune-related inflammatory symptoms and rare, severe reactions such as cytokine release syndrome and organ-specific toxicity. Therefore, the balance of evidence strongly supports the claim.

Evidence for · 5
Perioperative Care of Cancer Patients Treated with Immune Checkpoint Inhibitors: Current Evidence and Clinical Considerations-A Scoping Review.
2026
Perioperative Care of Cancer Patients Treated with Immune Checkpoint Inhibitors: Current Evidence and Clinical Considerations-A Scoping Review highlights that immune checkpoint inhibitors can generate immune-related adverse events such as pneumonitis and cytokine release syndrome that mimic
See more

Perioperative Care of Cancer Patients Treated with Immune Checkpoint Inhibitors: Current Evidence and Clinical Considerations-A Scoping Review highlights that immune checkpoint inhibitors can generate immune-related adverse events such as pneumonitis and cytokine release syndrome that mimic conventional complications.

Get citation
IR, C. & L, V. (2026). Perioperative Care of Cancer Patients Treated with Immune Checkpoint Inhibitors: Current Evidence and Clinical Considerations-A Scoping Review.. doi.org. https://doi.org/10.3390/cancers18162654

See more details
More for · 4
Efficacy and Safety of Immunotherapeutic Strategies for the Treatment of MART-1-Expressing Melanoma: Systematic Review of Clinical Trials.
2026
Efficacy and Safety of Immunotherapeutic Strategies for the Treatment of MART-1-Expressing Melanoma: Systematic Review of Clinical Trials notes that immunotherapies are associated with various immunologic challenges, including a high incidence of adverse effects and autoimmunity.
Get citation
A, A., S, T., E, G., P, T., & S, S. (2026). Efficacy and Safety of Immunotherapeutic Strategies for the Treatment of MART-1-Expressing Melanoma: Systematic Review of Clinical Trials.. doi.org. https://doi.org/10.3390/cancers18183016

Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes.
2026
Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes establishes that cytokine release syndrome induced by ICIs is a rare but severe immune-related adverse event presenting with fever and systemic symptoms.
Get citation
Q, J., Q, F., & B, F. (2026). Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes.. doi.org. https://doi.org/10.3389/fimmu.2026.1860219

Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management.
2026
Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management documents that immune-mediated muscle injury and myocarditis can be severe and lethal immune-related adverse events.
Get citation
O, d. l. B. B., M, M., ML, N. T., H, P., G, J., & P, L. (2026). Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management.. doi.org. https://doi.org/10.3389/fonc.2026.1910598

A review on toxicities of T-cell engager-based therapies in solid tumors.
2026
A review on toxicities of T-cell engager-based therapies in solid tumors discusses how T-cell engager therapies frequently trigger cytokine release syndrome and immune-mediated adverse events characterized by acute inflammatory responses.
Get citation
E, B., C, V., R, S., F, L., N, G., & E, R. (2026). A review on toxicities of T-cell engager-based therapies in solid tumors.. doi.org. https://doi.org/10.1177/17588359261467651

What does the evidence say?

The claim is specific, empirical, and directly addressed by multiple retrieved papers showing that cancer immunotherapy causes both common immune-related inflammatory symptoms and rare, severe reactions such as cytokine release syndrome and organ-specific toxicity. Therefore, the balance of evidence strongly supports the claim.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work